Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Diagnos Inc V.ADK

Alternate Symbol(s):  DGNOF

Diagnos Inc. is a Canadian company, which is engaged in early detection of critical health problems based on its FLAIRE artificial intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications, such as computer assisted retina analysis (CARA). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a tool for real-time screening of large volumes of patients. It provides software-based services to assist health specialists in the detection of diabetic retinopathy and other eye-related pathologies. Its geographical areas include Canada, the United States of America, Mexico, and Chile. The Company’s subsidiaries include Diagnos Internacional SA de CV and Diagnos Healthcare (India) Private Limited.


TSXV:ADK - Post by User

Bullboard Posts
Comment by scorpio40on Jun 07, 2017 11:51am
108 Views
Post# 26335629

RE:OTC Up-list already complete?

RE:OTC Up-list already complete?Follow the link and look at the top right hand next to the logo, it is still on the 'gray market', however the transition to the OTCQB should happen in a matter of days. https://www.otcmarkets.com/stock/DGNOF/quote

With regards to the article dated June 1st, 2017 available at
https://www.todayinmedicine.com/2017/06/01/diagnos-inc-issued-upside-market-valuation-in-research-report/
a key paragrah is ‘At this stage, however, in light of all the considerations mentioned previously, the story for DIAGNOS Inc. is not necessarily a quarter to quarter revenue story, nor is it about annual results year over year. The real story is a fundamental analysis regarding the ultimate adoption of large-scale medical systems of automated retinal screening – we believe such adoption is basically inevitable’.


scorp
Bullboard Posts